LU91883I2 - Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) - Google Patents

Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)

Info

Publication number
LU91883I2
LU91883I2 LU91883C LU91883C LU91883I2 LU 91883 I2 LU91883 I2 LU 91883I2 LU 91883 C LU91883 C LU 91883C LU 91883 C LU91883 C LU 91883C LU 91883 I2 LU91883 I2 LU 91883I2
Authority
LU
Luxembourg
Prior art keywords
veraflox
pradofloxacin
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU91883C
Other languages
English (en)
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201505&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91883(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of LU91883I2 publication Critical patent/LU91883I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
LU91883C 2003-08-13 2011-10-12 Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) LU91883I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10337191A DE10337191A1 (de) 2003-08-13 2003-08-13 Neue Verwendung von Chinolon-Antibiotika
PCT/EP2004/008629 WO2005018641A2 (fr) 2003-08-13 2004-08-02 Nouvelle utilisation d'antibiotiques du groupe quinolone

Publications (1)

Publication Number Publication Date
LU91883I2 true LU91883I2 (fr) 2013-04-12

Family

ID=34201505

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91883C LU91883I2 (fr) 2003-08-13 2011-10-12 Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)

Country Status (33)

Country Link
US (1) US8658645B2 (fr)
EP (1) EP1656143B1 (fr)
JP (2) JP5122814B2 (fr)
KR (1) KR101209119B1 (fr)
CN (1) CN100571702C (fr)
AR (2) AR045093A1 (fr)
AT (1) ATE528004T1 (fr)
AU (2) AU2004266452A1 (fr)
BR (1) BRPI0413509A (fr)
CA (1) CA2535637C (fr)
CY (1) CY1112167T1 (fr)
DE (1) DE10337191A1 (fr)
DK (1) DK1656143T3 (fr)
ES (1) ES2374728T3 (fr)
GT (1) GT200400156A (fr)
HK (1) HK1098687A1 (fr)
HR (1) HRP20120019T1 (fr)
IL (1) IL173655A (fr)
LU (1) LU91883I2 (fr)
MX (1) MXPA06001597A (fr)
MY (1) MY162652A (fr)
NO (1) NO333116B1 (fr)
NZ (1) NZ545261A (fr)
PE (1) PE20050341A1 (fr)
PL (1) PL1656143T3 (fr)
PT (1) PT1656143E (fr)
RU (1) RU2367437C2 (fr)
SI (1) SI1656143T1 (fr)
TW (1) TWI367095B (fr)
UA (1) UA85685C2 (fr)
UY (1) UY28465A1 (fr)
WO (1) WO2005018641A2 (fr)
ZA (1) ZA200601167B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
FR2896416B1 (fr) * 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
WO2010069493A1 (fr) * 2008-12-18 2010-06-24 Bayer Animal Health Gmbh Combinaison améliorée de principes actifs contenant un antibiotique et un médicament anti-inflammatoire non stéroïdien (nsaid)
CN102988280B (zh) * 2012-10-08 2014-03-19 新乡医学院 一种加雷沙星滴眼剂
JP6358868B2 (ja) * 2014-06-17 2018-07-18 Ｄｓファーマアニマルヘルス株式会社 オルビフロキサシンを含有する製剤組成物
CN106831795B (zh) * 2017-01-16 2018-12-21 石家庄学院 喹诺酮异土木香内酯衍生物及其制备和应用
CR20200502A (es) 2018-04-25 2020-12-22 Bayer Animal Health Gmbh Proceso para la hidrólisis de ésteres carboxílicos de quinolona
JP2023504249A (ja) * 2019-11-28 2023-02-02 バイエル・アクチエンゲゼルシヤフト 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62205060A (ja) * 1986-03-04 1987-09-09 Kyorin Pharmaceut Co Ltd ８位置換キノロンカルボン酸誘導体
DE3702393A1 (de) * 1987-01-28 1988-08-11 Bayer Ag 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel
DE59708771D1 (de) * 1996-02-23 2003-01-02 Bayer Ag Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo- 4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate
TW415943B (en) * 1996-06-28 2000-12-21 Bayer Ag 7-(3-vinyl-1,4-piperazin-1-yl)-substituted quinolonecarboxylic acids
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
DE19652219A1 (de) * 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(1-Aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl)-chinolon- und naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
AU3952397A (en) * 1997-08-22 1999-03-16 Dainippon Pharmaceutical Co. Ltd. Pyridonecarboxylic acid derivatives and intermediates for the preparation thereof
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika

Also Published As

Publication number Publication date
TWI367095B (en) 2012-07-01
UA85685C2 (ru) 2009-02-25
EP1656143B1 (fr) 2011-10-12
MXPA06001597A (es) 2006-05-19
AR109644A2 (es) 2019-01-09
HRP20120019T1 (hr) 2012-02-29
KR101209119B1 (ko) 2012-12-07
RU2006107497A (ru) 2006-08-10
ATE528004T1 (de) 2011-10-15
CN100571702C (zh) 2009-12-23
CA2535637C (fr) 2011-11-08
ZA200601167B (en) 2007-04-25
NO20061127L (no) 2006-03-08
GT200400156A (es) 2005-03-23
PE20050341A1 (es) 2005-07-07
MY162652A (en) 2017-06-30
DE10337191A1 (de) 2005-03-17
IL173655A (en) 2013-07-31
PL1656143T3 (pl) 2012-03-30
WO2005018641A3 (fr) 2005-10-06
DK1656143T3 (da) 2012-02-06
AU2011200356A1 (en) 2011-02-17
ES2374728T3 (es) 2012-02-21
NO333116B1 (no) 2013-03-04
JP2007501819A (ja) 2007-02-01
SI1656143T1 (sl) 2012-03-30
CN1867335A (zh) 2006-11-22
AU2004266452A1 (en) 2005-03-03
RU2367437C2 (ru) 2009-09-20
US20070082911A1 (en) 2007-04-12
CA2535637A1 (fr) 2005-03-03
AU2011200356B2 (en) 2012-01-12
TW200517110A (en) 2005-06-01
EP1656143A2 (fr) 2006-05-17
IL173655A0 (en) 2006-07-05
NZ545261A (en) 2009-11-27
AR045093A1 (es) 2005-10-12
US8658645B2 (en) 2014-02-25
PT1656143E (pt) 2012-01-12
JP2012211170A (ja) 2012-11-01
JP5122814B2 (ja) 2013-01-16
KR20060061353A (ko) 2006-06-07
BRPI0413509A (pt) 2006-10-10
UY28465A1 (es) 2005-03-31
HK1098687A1 (en) 2007-07-27
CY1112167T1 (el) 2015-12-09
WO2005018641A2 (fr) 2005-03-03

Similar Documents

Publication Publication Date Title
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU93093I2 (fr) Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU92336I2 (fr) Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LUC00127I1 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
LU93096I2 (fr) Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
AU2003264448A1 (en) Novel 6-substituted uracil derivative and therapeutic agent for allergic disease
ATE336264T1 (de) Dispergierbare pharmazeutische zusammensetzungen
CY2013011I2 (el) Μεθοδος χορηγησης διφωσφονικων
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
IL173986A0 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
EP1513825A4 (fr) Medicament anti-tuberculeux: compositions et methodes